CRX

Across TCGA pan-cancer cohorts, CRX Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CRX data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CRX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRX expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, LUSC, and BLCA are the cancer types where CRX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
LUSC	OS	Median	III,IV	0.147	0.664	.028	12	view →
BLCA	DFS	Median	All	0.194	0.627	.016	9	view →
SARC	OS	Median	All	0.178	0.745	.008	6	view →
SKCM	DFS	Median	All	1.000	0.731	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CRX–ESCA (DFS)

Open the ESCA breakdown →